logo
OM:EQL logo

EQL Pharma Community

OM:EQL Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

EQL logo
EQL Pharma
MA
Mandelman
Community Contributor

EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

Catalysts Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare. Market Niche & Protection: Its product is too small for major competitors to challenge, ensuring a stable, low‐competition environment.
View narrative
SEK 121.14
FV
34.4% undervalued intrinsic discount
30.00%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
about 2 months ago author updated this narrative